Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney function may change how obesity drug works

NCT ID NCT07347808

Knowledge-focused Sponsor: Vincentage Pharma Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a single dose of the drug VCT220 behaves in people with moderate kidney problems compared to those with healthy kidneys. Researchers measured drug levels in the blood and checked for side effects. The goal is to find the right dose for people with kidney issues. 16 adults aged 18-75 took part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

16 people

The number who actually took part.

Started

Dec 2025

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects aged 18 to 75 years * Body mass index (BMI) between 18.5 and 32.0 kg/m² * Able and willing to provide written informed consent * Willing to comply with contraception requirements * Moderate renal impairment group * Absolute eGFR ≥30 and \<60 mL/min * Diagnosis of chronic kidney disease for ≥3 months with stable renal function * Normal renal function group: Absolute eGFR ≥90 and \<130 mL/min Matched to moderate renal impairment subjects by sex, age (±10 years), and BMI (±10%) Exclusion Criteria: * History of hypersensitivity to GLP-1 receptor agonists or study drug components * History of hypoglycemia * History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 * History of pancreatitis * Clinically significant cardiovascular, hepatic, gastrointestinal, neurological, hematologic, endocrine, or psychiatric disease * Use of prohibited medications affecting drug metabolism prior to dosing * Positive tests for hepatitis B, hepatitis C, HIV, or syphilis * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

Contacts and locations

Locations

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.